Comparison of Aramchol Concentrations With Once or Twice Daily Dosing

A Randomised, Open-label Study to Compare Plasma Concentrations of Aramchol in Healthy Volunteers After Once or Twice Daily Oral Dosing to Steady State

The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily and 600 mg once daily.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Aramchol

Detailed Description

The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily (every 12 h) for 9 days in one period, with a single dose in the morning of Day 10, and 600 mg once daily (every 24 h) for 10 days in the other period. A pharmacokinetic profile will be obtained over the dosing interval on Day 10 of each period.

Enrolment of 16 subjects is planned with each subject taking part in the 2 study periods. The subjects will be randomised 1:1 so that 8 subjects receive each regimen in the first period and the alternate regimen in the second period.

Subjects will be screened within 21 days before their first dose of study medicine. In each period they will remain resident on the ward from Day -1 until the morning of Day 11. Subjects will attend a follow-up visit 14 days (±2 days) after the end of the second period. There will be an interval of at least 7 days between Periods 1 and 2.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, NW10 7EW
    • Hammersmith Medicines Research (HMR)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female healthy volunteer.
2. Aged 18-45 years at time of consent.
3. A body mass index (BMI; Quetelet index) in the range 18.0-30.9.
4. Ability to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
5. Willingness to give written consent to participate after reading and understanding the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.
6. Agree to use effective contraception as described in Section 11.
7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).

Exclusion Criteria:

1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception (see Section 11).
2. Of East Asian descent including, but not limited to, Chinese, Japanese, Korean, Mongolian, or Vietnamese.
3. Smoker, or has smoked cigarettes or other tobacco or nicotine products in the last 12 months.
4. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (AP) >ULN at the screening visit. A repeat is allowed on one occasion for determination of eligibility.
6. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
7. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including gastrointestinal disorder or of oesophageal, gastric, biliary or intestinal surgery (excluding herniotomy and appendectomy).
8. Use of anticholinergic or other drugs known to affect gastrointestinal motility during the 7 days before the first dose of trial medication.
9. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
10. Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
11. Presence or history of severe adverse reaction to any drug or a history of sensitivity to aramchol, cholic acid, bile acid sequestrants, or any excipients in the tablets.
12. Use of a prescription medicine (except oral contraceptives in females), or any other medicine or herbal remedy (including St John's wort) known to interfere with enzymes in the liver, during the 28 days before the first dose of trial medication; or use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.
13. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before first admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
14. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
15. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 100-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45_90 beats/min, unless judged not clinically significant. Borderline values (ie values that are within 5 mm Hg for blood pressure or 5 beats/min for heart rate) will be repeated. Subjects can be included if the repeat value is within range or still borderline, but deemed not clinically significant by the investigator.
16. Possibility that the volunteer will not cooperate with the requirements of the protocol.
17. Evidence of drug abuse on urine testing.
18. Positive test for hepatitis B, hepatitis C or HIV.
19. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
20. Objection by GP to volunteer entering trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Aramchol 300 mg; Aramchol 300 mg twice daily (every 12 hours)	Drug: Aramchol; One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
Experimental: Aramchol 600 mg; Aramchol 600 mg once daily (every 24 hours)	Drug: Aramchol; One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK) of aramchol	AUC	PK parameters will be measured on Days 7, 8 , 9, and 10.
Pharmacokinetics of aramchol	Cavg	PK parameters will be measured on Days 7, 8 , 9, and 10.
PK of aramchol	Ctau	PK parameters will be measured on Days 7, 8 , 9, and 10.
Pharmacokinetics (PK) of aramchol	Tmax	K parameters will be measured on Days 7, 8 , 9, and 10.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vital signs and physical examination	Systolic and diastolic blood pressure, Heart rate, Oral temperature and Respiratory rate	During both treatment periods vital signs will be assessed on Days 1, 5 and 10.
Electrocardiogram	12-lead ECGs	During both treatment periods ECG will be assessed on Days 1, 5 and 10.
Laboratory safety tests: Biochemistry	Usual tests.	On Day -1, Day 5,on Day 11.
Laboratory safety tests: Hematology	haemoglobin, red blood cells, mean corpuscular volume , mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haematocrit, white blood cells and platelets.	On Day -1, Day 5,on Day 11.
Laboratory safety tests: Urinalysis	Usual Dipstick test	On Day -1, Day 5,on Day 11.
Safety and tolerability: Adverse events (AEs).	Adverse events are collected during entire study period.	From screening visit to 14 days after the last dose in period 2.

Collaborators and Investigators

• Sponsor: Galmed Pharmaceuticals Ltd
• Collaborators: Hammersmith Medicines Research; Diamond Pharma Services Regulatory Affairs Consultancy; Analyst Research Laboratories
• Investigators: Principal Investigator: Adeep Puri, M.D., Hammersmith Medicines Research

Study record dates

Study Major Dates

• Study Start (Actual): December 8, 2018
• Primary Completion (Actual): February 3, 2019
• Study Completion (Actual): March 5, 2019

Study Registration Dates

• First Submitted: November 29, 2018
• First Submitted That Met QC Criteria: December 11, 2018
• First Posted (Actual): December 12, 2018

Study Record Updates

• Last Update Posted (Actual): August 9, 2019
• Last Update Submitted That Met QC Criteria: August 8, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: Aramchol 017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes